LIVIVO - Search results -

Search results

Result 1 - 10 of total 2990

Search options

Article ; Online: U.S. Older Adults' Participation in Balance Activities.

Hyde, Eric T / Omura, John D / Chen, Tiffany J / Brown, David R / Fulton, Janet E / Carlson, Susan A

Journal of aging and physical activity

2021 Volume 29, Issue 6, Page(s) 1003–1009

Abstract: ... activities. The authors estimated the prevalence of U.S. older adults (age ≥65 years) who do balance ...

Abstract	The Physical Activity Guidelines for Americans, second edition recommends that older adults do multicomponent physical activity, which includes balance training in addition to aerobic and muscle-strengthening activities. The authors estimated the prevalence of U.S. older adults (age ≥65 years) who do balance activities and meet the aerobic and muscle-strengthening physical activity guidelines. The authors analyzed data on 1,012 respondents to the 2019 FallStyles survey, a nationwide web-based panel survey. Approximately four in 10 respondents (40.7%) reported doing balance activities on ≥1 day/week, 34.0% on ≥2 days/week, and 25.3% on ≥3 days/week. Prevalence differed by sex, education level, income level, census region, body mass index category, and meeting the aerobic and/or muscle-strengthening guidelines. The combined prevalence of participation in balance activities and meeting aerobic and muscle-strengthening guidelines ranged from 12.0% for ≥3 days/week to 15.8% for ≥1 day/week. Opportunities exist to introduce and increase participation in balance and multicomponent activities by older adults.
MeSH term(s)	Aged ; Body Mass Index ; Exercise ; Exercise Therapy ; Humans ; Prevalence ; United States
Language	English
Publishing date	2021-06-30
Publishing country	United States
Document type	Journal Article
ISSN	1543-267X
ISSN (online)	1543-267X
DOI	10.1123/japa.2020-0422
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Disparities in Youth Sports Participation in the U.S., 2017-2018.

Hyde, Eric T / Omura, John D / Fulton, Janet E / Lee, Sarah M / Piercy, Katrina L / Carlson, Susan A

American journal of preventive medicine

2020 Volume 59, Issue 5, Page(s) e207–e210

Abstract: ... analysis, interpretation, and dissemination of U.S. youth sports surveillance data. The purpose ... of this study is to provide the recent national estimates of U.S. youth aged 6-17 years who participate ... logistic regression models.: Results: Overall, 57.7% (95% CI=56.6, 58.9) of U.S. youth participated in sports ...

Abstract	Introduction: In 2019, the National Youth Sports Strategy was released and called for regular analysis, interpretation, and dissemination of U.S. youth sports surveillance data. The purpose of this study is to provide the recent national estimates of U.S. youth aged 6-17 years who participate in sports and examine the differences in participation by demographic characteristics, overall and across age groups. Methods: Nationally representative data on parent-reported youth sports participation from the 2017-2018 National Survey of Children's Health (n=36,779) were analyzed in 2019. The prevalence and 95% CIs of youth sports participation were estimated by demographic characteristics, overall and by age group. Investigators assessed the significant (p<0.05) differences and trends in participation using pairwise t-tests and orthogonal polynomial contrasts and effect modification by age group using logistic regression models. Results: Overall, 57.7% (95% CI=56.6, 58.9) of U.S. youth participated in sports. Participation was highest among youth who were aged 10-13 years, male, and white, non-Hispanic and increased with increasing parent/caregiver education and household income (all p<0.05). Differences in participation by demographic characteristics were more pronounced among younger youth. For example, prevalence by household income level ranged from 32.7% to 79.9% among children aged 6-9 years and from 41.6% to 67.2% among youth aged 14-17 years. Conclusions: Although nearly 6 in 10 U.S. youth participate in sports, substantial disparities exist, especially among younger children. Identifying and overcoming the barriers may help increase youth sports participation in the U.S.
MeSH term(s)	Adolescent ; Child ; European Continental Ancestry Group ; Humans ; Male ; Parents ; Sports ; Surveys and Questionnaires ; Youth Sports
Language	English
Publishing date	2020-07-30
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	632646-8
ISSN	1873-2607 ; 0749-3797
ISSN (online)	1873-2607
ISSN	0749-3797
DOI	10.1016/j.amepre.2020.05.011
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2096: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Phase I study of preoperative chemoradiotherapy with sequential oxaliplatin and irinotecan with S-1 for locally advanced rectal cancer.

Fujikawa, Hiroyuki / Toiyama, Yuji / Inoue, Yasuhiro / Omura, Yusuke / Ide, Shozo / Kitajima, Takahito / Yasuda, Hiromi / Okugawa, Yoshinaga / Okita, Yoshiki / Yoshiyama, Shigeyuki / Hiro, Junichiro / Kobayashi, Minako / Ohi, Masaki / Araki, Toshimitsu / Kusunoki, Masato

Oncology letters

2019 Volume 17, Issue 4, Page(s) 3930–3936

Abstract: ... and irinotecan with S-1 for locally advanced rectal cancer (LARC). This phase I study evaluated ... the maximum tolerated dose and recommended dose (RD) of oxaliplatin following irinotecan with S-1. Patients with clinical ... with fixed doses of S-1 (80 mg/m ...

Abstract	The present study designed a novel preoperative chemoradiotherapy (CRT) with sequential oxaliplatin and irinotecan with S-1 for locally advanced rectal cancer (LARC). This phase I study evaluated the maximum tolerated dose and recommended dose (RD) of oxaliplatin following irinotecan with S-1. Patients with clinical stage T3 or 4 or involvement of the regional nodes and no evidence of distant metastases were treated with fixed doses of S-1 (80 mg/m
Language	English
Publishing date	2019-02-08
Publishing country	Greece
Document type	Journal Article
ZDB-ID	2573196-8
ISSN	1792-1082 ; 1792-1074
ISSN (online)	1792-1082
ISSN	1792-1074
DOI	10.3892/ol.2019.10028
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Cytosporone S with antimicrobial activity, isolated from the fungus Trichoderma sp. FKI-6626.

Ishii, Takahiro / Nonaka, Kenichi / Suga, Takuya / Masuma, Rokuro / Ōmura, Satoshi / Shiomi, Kazuro

Bioorganic & medicinal chemistry letters

2013 Volume 23, Issue 3, Page(s) 679–681

Abstract: A new microbial metabolite, cytosporone S (1) was isolated from a fermentation broth of the fungus ...

Abstract	A new microbial metabolite, cytosporone S (1) was isolated from a fermentation broth of the fungus Trichoderma sp. FKI-6626. Its chemical structure was determined primarily by NMR spectroscopy and mass spectrometry. Compound 1 showed antimicrobial activity against several Gram-positive and Gram-negative bacteria and fungi.
MeSH term(s)	Anti-Bacterial Agents/chemistry ; Anti-Bacterial Agents/isolation & purification ; Anti-Bacterial Agents/pharmacology ; Antifungal Agents/chemistry ; Antifungal Agents/isolation & purification ; Antifungal Agents/pharmacology ; Bacteria/drug effects ; Benzopyrans/chemistry ; Benzopyrans/isolation & purification ; Benzopyrans/pharmacology ; Fungi/drug effects ; Magnetic Resonance Spectroscopy ; Microbial Sensitivity Tests ; Trichoderma/chemistry
Chemical Substances	Anti-Bacterial Agents ; Antifungal Agents ; Benzopyrans ; cytosporone S
Language	English
Publishing date	2013-02-01
Publishing country	England
Document type	Journal Article
ZDB-ID	1063195-1
ISSN	1464-3405 ; 0960-894X
ISSN (online)	1464-3405
ISSN	0960-894X
DOI	10.1016/j.bmcl.2012.11.113
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3203: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Immunoregulation of Theiler’s virus-induced demyelinating disease by glatiramer acetate without suppression of antiviral immune responses

Omura, Seiichi / Sato, Fumitaka / Martinez, NicholasE / Range, Tierra / Ekshyyan, Lesya / Minagar, Alireza / Alexander, J.Steven / Tsunoda, Ikuo

Archives of virology. 2018 May, v. 163, no. 5

2018

Abstract: ... with Theiler’s murine encephalomyelitis virus (TMEV). Treatment of TMEV-infected mice with GA neither enhanced viral loads nor suppressed ...

Abstract	While most disease-modifying drugs (DMDs) regulate multiple sclerosis (MS) by suppressing inflammation, they can potentially suppress antiviral immunity, causing progressive multifocal leukoencephalopathy (PML). The DMD glatiramer acetate (GA) has been used for MS patients who are at high risk of PML. We investigated whether GA is safe for use in viral infections by using a model of MS induced by infection with Theiler’s murine encephalomyelitis virus (TMEV). Treatment of TMEV-infected mice with GA neither enhanced viral loads nor suppressed antiviral immune responses, while it resulted in an increase in the Foxp3/Il17a ratio and IL-4/IL-10 production. This is the first study to suggest that GA could be safe for MS patients with a proven viral infection.
Keywords	acetates ; drugs ; immune response ; immunomodulation ; inflammation ; mice ; models ; patients ; risk ; sclerosis ; viral load
Language	English
Dates of publication	2018-05
Size	p. 1279-1284.
Publishing place	Springer Vienna
Document type	Article
ZDB-ID	7491-3
ISSN	1432-8798 ; 0304-8608
ISSN (online)	1432-8798
ISSN	0304-8608
DOI	10.1007/s00705-018-3729-6
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Bonn / Germany

Z 70/128: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: My gratitude for Arny's friendship with me.

Õmura, Satoshi

Journal of industrial microbiology & biotechnology

2021 Volume 48, Issue 9-10

MeSH term(s)	Friends ; Humans
Language	English
Publishing date	2021-12-05
Publishing country	Germany
Document type	Journal Article
ZDB-ID	1482484-X
ISSN	1476-5535 ; 1367-5435
ISSN (online)	1476-5535
ISSN	1367-5435
DOI	10.1093/jimb/kuab081
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article: [A case of a patient with gastric cancer and peritoneal dissemination who survived for more than 10 years after successful treatment with S-1].

Yamamura, Akihiro / Ono, Fuminori / Hiraga, Masaki / Omura, Noriyuki / Takano, Naruhisa / Sato, Hideaki / Toyama, Shingo / Onochi, Shoichi

Gan to kagaku ryoho. Cancer & chemotherapy

2014 Volume 41, Issue 6, Page(s) 773–775

Abstract: ... chose an oral anticancer drug, S-1, as a postoperative chemotherapy agent. S-1 was administered ... at a dose of 100mg/body/day for 4 weeks, followed by a 2- week rest. There were no adverse events due to S-1 ... and no exacerbation of peritoneal dissemination in the 5 years following surgery. The S-1 ...

Abstract	A 50-year-old female patient underwent distal gastrectomy and intraperitoneal CDDP administration for advanced gastric cancer accompanied by severe peritoneal dissemination. She valued her quality of life and chose an oral anticancer drug, S-1, as a postoperative chemotherapy agent. S-1 was administered at a dose of 100mg/body/day for 4 weeks, followed by a 2- week rest. There were no adverse events due to S-1 and no exacerbation of peritoneal dissemination in the 5 years following surgery. The S-1 administration schedule was then changed to alternate-day administration. Eight years after the surgery, the patient discontinued S-1 treatment and has since survived for 11 years with no obvious cancer recurrence.
MeSH term(s)	Antimetabolites, Antineoplastic/therapeutic use ; Combined Modality Therapy ; Drug Combinations ; Female ; Gastrectomy ; Humans ; Lymph Node Excision ; Lymphatic Metastasis ; Middle Aged ; Neoplasm Invasiveness ; Oxonic Acid/therapeutic use ; Peritoneal Neoplasms/drug therapy ; Peritoneal Neoplasms/secondary ; Stomach Neoplasms/drug therapy ; Stomach Neoplasms/pathology ; Stomach Neoplasms/surgery ; Tegafur/therapeutic use ; Treatment Outcome
Chemical Substances	Antimetabolites, Antineoplastic ; Drug Combinations ; S 1 (combination) (150863-82-4) ; Tegafur (1548R74NSZ) ; Oxonic Acid (5VT6420TIG)
Language	Japanese
Publishing date	2014-06
Publishing country	Japan
Document type	Case Reports ; English Abstract ; Journal Article
ZDB-ID	604842-0
ISSN	0385-0684
ISSN	0385-0684
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2573: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy.

Omura, Tetsuya / Shimada, Yutaka / Nagata, Takuya / Okumura, Tomoyuki / Fukuoka, Junya / Yamagishi, Fuminori / Tajika, Sadakatsu / Nakajima, Sanae / Kawabe, Atsushi / Tsukada, Kazuhiro

Oncology reports

2014 Volume 31, Issue 2, Page(s) 613–618

Abstract: S-1 has been recommended as adjuvant chemotherapy in patients after curative surgery ... for gastric cancer. However, some patients suffer recurrence even after S-1 adjuvant chemotherapy. The present study ... was conducted to find a predictive marker of the efficacy of S-1 adjuvant chemotherapy. We examined ...

Abstract	S-1 has been recommended as adjuvant chemotherapy in patients after curative surgery for gastric cancer. However, some patients suffer recurrence even after S-1 adjuvant chemotherapy. The present study was conducted to find a predictive marker of the efficacy of S-1 adjuvant chemotherapy. We examined the microRNA (miRNA) expression of 35 patients who underwent S-1 adjuvant chemotherapy after curative surgery (R0) for pathological stage II or III gastric cancer. miRNAs were extracted from formalin-fixed, paraffin-embedded specimens for analysis and miRNA expression was examined using miRNA oligo chips. Fifteen patients relapsed and 20 did not over 5 years. Five miRNAs (miR-92b, 422a, 4732-5p, 4758-3p and 221) were highly expressed according to the tumor/normal (T/N) ratio in the patients who relapsed but not in those who did not relapse (P-value <0.05) by microarray analysis. If tumors showed high expression of 4 miRNAs (miR-92b, 422a, 4732-5p and 4758-3p) their positive predictive value of relapse was 93.8% and negative predictive value was 92.3%. In this case, their disease-free survival rate and overall survival rate were very poor. Our findings indicate that miR-92b, miR‑422a, miR-4732-5p and miR-4758-3p are closely associated with relapse following S-1 adjuvant chemotherapy in gastric cancer.
MeSH term(s)	Aged ; Antimetabolites, Antineoplastic/therapeutic use ; Chemotherapy, Adjuvant ; Disease-Free Survival ; Drug Combinations ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Male ; MicroRNAs/genetics ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/mortality ; Oxonic Acid/therapeutic use ; Stomach Neoplasms/drug therapy ; Stomach Neoplasms/genetics ; Stomach Neoplasms/mortality ; Survival ; Tegafur/therapeutic use
Chemical Substances	Antimetabolites, Antineoplastic ; Drug Combinations ; MicroRNAs ; S 1 (combination) (150863-82-4) ; Tegafur (1548R74NSZ) ; Oxonic Acid (5VT6420TIG)
Language	English
Publishing date	2014-02
Publishing country	Greece
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1222484-4
ISSN	1791-2431 ; 1021-335X
ISSN (online)	1791-2431
ISSN	1021-335X
DOI	10.3892/or.2013.2900
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4213: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Multicenter phase II trial of preoperative chemoradiotherapy with S-1 for locally advanced oral squamous cell carcinoma.

Harada, Hiroyuki / Omura, Ken / Tomioka, Hirofumi / Nakayama, Hideki / Hiraki, Akimitsu / Shinohara, Masanori / Yoshihama, Yasuto / Shintani, Satoru

Cancer chemotherapy and pharmacology

2013 Volume 71, Issue 4, Page(s) 1059–1064

Abstract: Purpose: We evaluated whether preoperative chemotherapy with S-1 and concurrent radiotherapy is ... received a total radiation dose of 40 Gy, in once-daily 2-Gy fractions, and received S-1 at 65 mg/m(2)/day ... years were 91.5, 83.8, and 83.8 %, respectively.: Conclusion: Concurrent administration of S-1 and ...

Abstract	Purpose: We evaluated whether preoperative chemotherapy with S-1 and concurrent radiotherapy is feasible and efficacious in the treatment of advanced oral squamous cell carcinoma. Methods: Participants comprised 39 patients with oral carcinoma (stage III, n = 15; stage IVA, n = 24). All patients received a total radiation dose of 40 Gy, in once-daily 2-Gy fractions, and received S-1 at 65 mg/m(2)/day for 5 consecutive days, over 4 consecutive weeks with concurrent radiotherapy. Results: Hematological toxicity was mild and reversible. The most common non-hematological toxicity was grade 3 mucositis, but this was transient and tolerable. Radical surgery was performed for 37 patients, with the remaining 2 patients declining the surgery. Postoperatively, local failure developed in 1 patient, and neck failure in 2 patients. Distant metastases were identified in 4 patients. At a median follow-up of 38.0 months (range 23-88 months), locoregional control, disease-specific survival, and overall survival rates at 3 years were 91.5, 83.8, and 83.8 %, respectively. Conclusion: Concurrent administration of S-1 and radiotherapy combined with surgery offers a well-tolerated method of successfully treating advanced oral squamous cell carcinoma. The locoregional control rate remains high even at 3 years of follow-up, and no serious adverse effects have been encountered.
MeSH term(s)	Adult ; Aged ; Antimetabolites, Antineoplastic/adverse effects ; Antimetabolites, Antineoplastic/therapeutic use ; Carcinoma, Squamous Cell/mortality ; Carcinoma, Squamous Cell/therapy ; Chemoradiotherapy ; Drug Combinations ; Female ; Humans ; Male ; Middle Aged ; Mouth Neoplasms/mortality ; Mouth Neoplasms/therapy ; Oxonic Acid/adverse effects ; Oxonic Acid/therapeutic use ; Survival Rate ; Tegafur/adverse effects ; Tegafur/therapeutic use
Chemical Substances	Antimetabolites, Antineoplastic ; Drug Combinations ; S 1 (combination) (150863-82-4) ; Tegafur (1548R74NSZ) ; Oxonic Acid (5VT6420TIG)
Language	English
Publishing date	2013-02-03
Publishing country	Germany
Document type	Clinical Trial, Phase II ; Journal Article ; Multicenter Study
ZDB-ID	6820-2
ISSN	1432-0843 ; 0344-5704 ; 0943-9404
ISSN (online)	1432-0843
ISSN	0344-5704 ; 0943-9404
DOI	10.1007/s00280-013-2101-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1420: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Gramicidin S identified as a potent inhibitor for cytochrome bd-type quinol oxidase.

Mogi, Tatsushi / Ui, Hideaki / Shiomi, Kazuro / Omura, Satoshi / Kita, Kiyoshi

FEBS letters

2008 Volume 582, Issue 15, Page(s) 2299–2302

Abstract: Gramicidin S, a cationic cyclic decapeptide, exhibits the potent antibiotic activity ... we identified gramicidin S as a potent inhibitor for cytochrome bd-type quinol oxidase from Escherichia coli ... We found that gramicidin S inhibited the oxidase with IC(50) of 3.5 microM by decreasing V(max) and ...

Abstract	Gramicidin S, a cationic cyclic decapeptide, exhibits the potent antibiotic activity through perturbation of lipid bilayers of the bacterial membrane. From the screening of natural antibiotics, we identified gramicidin S as a potent inhibitor for cytochrome bd-type quinol oxidase from Escherichia coli. We found that gramicidin S inhibited the oxidase with IC(50) of 3.5 microM by decreasing V(max) and the affinity for substrates but showed the stimulatory effect at low concentrations. Our findings would provide a new insight into the development of gramicidin S analogs, which do not share the target and mechanism with conventional antibiotics.
MeSH term(s)	Anti-Bacterial Agents/pharmacology ; Cell Membrane/enzymology ; Cytochromes/antagonists & inhibitors ; Detergents/chemistry ; Electron Transport Chain Complex Proteins/antagonists & inhibitors ; Enzyme Inhibitors/pharmacology ; Escherichia coli/drug effects ; Escherichia coli/enzymology ; Escherichia coli/growth & development ; Escherichia coli Proteins/antagonists & inhibitors ; Gramicidin/pharmacology ; Inhibitory Concentration 50 ; Micelles ; Models, Chemical ; Oxidoreductases/antagonists & inhibitors
Chemical Substances	Anti-Bacterial Agents ; Cytochromes ; Detergents ; Electron Transport Chain Complex Proteins ; Enzyme Inhibitors ; Escherichia coli Proteins ; Micelles ; Gramicidin (1405-97-6) ; Oxidoreductases (EC 1.-) ; cytochrome bd terminal oxidase complex, E coli (EC 1.9.3.-)
Language	English
Publishing date	2008-06-25
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	212746-5
ISSN	1873-3468 ; 0014-5793
ISSN (online)	1873-3468
ISSN	0014-5793
DOI	10.1016/j.febslet.2008.05.031
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.B 282: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito